Zealand Pharma A/S
ZEAL
Rangering i aksjer
#5540
Zealand Pharma A/S is a Danish biotechnology firm dedicated to the... Zealand Pharma A/S is a Danish biotechnology firm dedicated to the identification, progression, and market introduction of peptide-based therapeutics. The company concentrates its efforts on treatments for gastrointestinal and metabolic ailments, as well as other specialized conditions where current medical options are insufficient. Its commercialized product, Dasiglucagon, is an injectable solution provided in a pre-filled syringe or autoinjector, used to address severe hypoglycemia. Furthermore, Zealand Pharma is actively developing Dasiglucagon for inclusion in bi-hormone artificial pancreas systems that integrate both insulin and dasiglucagon. The compound Dasiglucagon is also undergoing late-stage (Phase III) clinical trials for congenital hyperinsulinism. Another significant asset in its development pipeline is glepaglutide, a long-acting GLP-2 analog, which is likewise in Phase III clinical studies for treating short bowel syndrome. Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma A/S maintains strategic alliances with a range of partners, including Sanofi-Aventis Deutschland GmbH, Boehringer Ingelheim International GmbH, Alexion Pharmaceuticals, Inc., and Beta Bionics, Inc.
Aksjekurs
$34.59
Markedsverdi
$2.40B
Endring (1 dag)
-0.95%
Endring (1 år)
-52.20%
Land
DK
Handel Zealand Pharma A/S (ZEAL)
Kategori
Healthcare
Aksjeprishistorikk for Zealand Pharma A/S (ZEAL)
Høyeste sluttskurs: $36.07 den 2026-10-01
Laveste sluttskurs: $14.13 den 2013-02-01
Laveste sluttskurs: $14.13 den 2013-02-01
Aksjeprishistorikk for Zealand Pharma A/S fra 2013 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | -28.90% |
| 2025 | -27.05% |
| 2024 | 103.83% |
| 2023 | 83.97% |
| 2022 | 12.44% |
| 2021 | -30.48% |
| 2020 | 12.58% |
| 2019 | 163.90% |
| 2018 | -13.34% |
| 2017 | -14.27% |
| 2016 | -23.32% |
| 2015 | 66.31% |
| 2014 | 25.21% |
| 2013 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $757.97 | 7.73% |
CH
|
